China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
China Resources Pharmaceutical Group Co., Ltd. (HKG: 3320) announced plans to sell a 17.87% stake in...
HKG: 3320
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within...
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong...
China Resources Partners with Fosun Pharma to Expand Global Healthcare Footprint
China Resources (Holdings) Co. Ltd (HKG: 3320) has entered into a strategic partnership with compatriot...
China Resources Pharma Reports Strong Interim Results Amid COVID-19
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...